Pacira Pharmaceuticals Company Profile (NASDAQ:PCRX)

About Pacira Pharmaceuticals

Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company's lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: PCRX
  • CUSIP: 69512710
Key Metrics:
  • Previous Close: $43.70
  • 50 Day Moving Average: $39.36
  • 200 Day Moving Average: $37.11
  • 52-Week Range: $37,402,000.00 - $29.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 46.49
  • P/E Growth: 1.54
  • Market Cap: $1.63B
  • Outstanding Shares: 37,402,000
  • Beta: 2.24
Profitability:
  • Net Margins: -13.37%
  • Return on Equity: -1.52%
  • Return on Assets: -0.86%
Debt:
  • Current Ratio: 1.60%
  • Quick Ratio: 1.35%
Additional Links:
Companies Related to Pacira Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Pacira Pharmaceuticals (NASDAQ:PCRX) (?)
Ratings Breakdown: 5 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.58)
Consensus Price Target: $60.10 (37.53% upside)

Analysts' Ratings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Show:
DateFirmActionRatingPrice TargetDetails
2/8/2017WedbushReiterated RatingOutperform$89.00View Rating Details
2/2/2017Jefferies Group LLCSet Price TargetBuy$53.00View Rating Details
1/28/2017MizuhoReiterated RatingBuy$41.00 -> $50.00View Rating Details
1/25/2017Cowen and CompanyReiterated RatingHoldView Rating Details
1/25/2017HC WainwrightSet Price TargetBuy$46.00 -> $48.00View Rating Details
1/10/2017BMO Capital MarketsReiterated RatingMarket Perform$35.00View Rating Details
12/30/2016Janney Montgomery ScottBoost Price TargetNeutral$31.00 -> $34.00View Rating Details
12/1/2016Goldman Sachs Group, Inc. (The)Initiated CoverageBuy -> Neutral$36.00View Rating Details
10/7/2016Brean CapitalInitiated CoverageHoldView Rating Details
8/3/2016Piper Jaffray CompaniesReiterated RatingOverweight$81.00View Rating Details
4/20/2016Canaccord GenuityReiterated RatingBuyView Rating Details
2/28/2016NomuraReiterated RatingBuy$100.00View Rating Details
1/29/2016Bank of America CorpUpgradeNeutral -> Buy$75.00View Rating Details
1/9/2016Leerink SwannReiterated RatingHoldView Rating Details
1/6/2016JMP SecuritiesReiterated RatingMkt Outperform$92.00View Rating Details
9/24/2015Barclays PLCReiterated RatingBuyView Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017ListenView Earnings Details
11/2/2016Q316($0.02)$0.20$67.16 million$68.40 millionViewListenView Earnings Details
8/4/2016Q216$0.03$0.19$67.80 million$69.60 millionViewListenView Earnings Details
5/2/2016Q116$0.07$0.15$67.11 million$65.50 millionViewListenView Earnings Details
2/25/2016Q415$0.27$0.20$68.40 million$69.30 millionViewListenView Earnings Details
10/27/2015Q315$0.15$0.10$60.44 million$62.20 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.20$62.97 million$59.10 millionViewListenView Earnings Details
4/30/2015Q115$0.02$0.05$61.11 million$58.30 millionViewListenView Earnings Details
2/24/2015Q4$0.27$0.35$61.62 million$61.80 millionViewListenView Earnings Details
10/30/2014Q314$0.10$0.14$52.20 million$52.00 millionViewListenView Earnings Details
7/31/2014Q214($0.21)$0.04$42.20 million$47.20 millionViewListenView Earnings Details
5/1/2014Q1($0.32)($0.19)$35.40 million$36.70 millionViewListenView Earnings Details
2/25/2014Q4($0.31)($0.33)ViewListenView Earnings Details
10/31/2013Q313($0.35)($0.30)$22.10 million$23.30 millionViewListenView Earnings Details
11/1/2012Q312($0.44)($0.49)$7.85 million$8.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)
Current Year EPS Consensus Estimate: $0.55 EPS
Next Year EPS Consensus Estimate: $0.94 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.20)($0.20)($0.20)
Q3 20161$0.03$0.03$0.03
Q4 20161$0.00$0.00$0.00
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Insider Ownership Percentage: 6.90%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/17/2017David M. StackCEOSell15,000$38.41$576,150.00View SEC Filing  
1/17/2017James S ScibettaPresidentSell20,000$38.53$770,600.00View SEC Filing  
8/15/2016David M. StackCEOSell15,000$45.32$679,800.00View SEC Filing  
8/15/2016James S. ScibettaPresidentSell25,000$45.21$1,130,250.00View SEC Filing  
6/7/2016Lauren Bullaro RikerVPSell938$47.66$44,705.08View SEC Filing  
6/6/2016Kristen Marie WilliamsCAOSell600$47.20$28,320.00View SEC Filing  
6/6/2016Lauren Bullaro RikerVPSell321$47.20$15,151.20View SEC Filing  
6/6/2016Mark A KronenfeldDirectorSell900$46.95$42,255.00View SEC Filing  
4/15/2016David M StackCEOSell25,000$64.14$1,603,500.00View SEC Filing  
1/29/2016Scott BraunsteinSVPBuy2,000$58.92$117,840.00View SEC Filing  
1/27/2016James B JonesSVPBuy500$62.50$31,250.00View SEC Filing  
1/15/2016David M. StackCEOSell15,000$63.84$957,600.00View SEC Filing  
1/12/2016James B JonesSVPBuy1,000$66.00$66,000.00View SEC Filing  
1/12/2016John P Phd LongeneckerDirectorBuy300$66.55$19,965.00View SEC Filing  
10/15/2015David M. StackCEOSell15,000$37.57$563,550.00View SEC Filing  
9/11/2015James S ScibettaCFOBuy5,000$61.37$306,850.00View SEC Filing  
8/17/2015Paul J HastingsDirectorSell3,000$60.02$180,060.00View SEC Filing  
7/15/2015David M StackCEOSell15,000$67.78$1,016,700.00View SEC Filing  
4/15/2015David M StackCEOSell25,000$90.50$2,262,500.00View SEC Filing  
4/10/2015Paul J HastingsDirectorSell2,500$88.00$220,000.00View SEC Filing  
3/16/2015Lauren Bullaro RikerDirectorSell5,000$95.34$476,700.00View SEC Filing  
3/13/2015Gary W PaceDirectorBuy1,000$93.83$93,830.00View SEC Filing  
2/6/2015James S ScibettaCFOSell15,000$111.22$1,668,300.00View SEC Filing  
1/15/2015David M StackCEOSell15,000$97.52$1,462,800.00View SEC Filing  
1/12/2015Paul J HastingsDirectorSell2,500$94.06$235,150.00View SEC Filing  
12/29/2014John P Phd LongeneckerDirectorSell1,000$93.32$93,320.00View SEC Filing  
12/5/2014Dennis L WingerDirectorBuy2,645$94.54$250,058.30View SEC Filing  
11/7/2014James S ScibettaCFOSell15,000$87.18$1,307,700.00View SEC Filing  
11/7/2014Taunia MarkvickaSVPBuy230$86.62$19,922.60View SEC Filing  
10/10/2014Paul J HastingsDirectorSell2,500$94.87$237,175.00View SEC Filing  
9/29/2014John P Phd LongeneckerDirectorSell1,000$96.40$96,400.00View SEC Filing  
8/29/2014Andreas WickiDirectorSell21,494$108.11$2,323,716.34View SEC Filing  
8/27/2014Andreas WickiDirectorSell55,813$108.08$6,032,269.04View SEC Filing  
8/26/2014Andreas WickiDirectorSell24,207$108.11$2,617,018.77View SEC Filing  
8/25/2014Andreas WickiDirectorSell30,000$108.07$3,242,100.00View SEC Filing  
8/11/2014Andreas WickiDirectorSell150,000$101.25$15,187,500.00View SEC Filing  
8/8/2014James S ScibettaCFOSell15,000$99.63$1,494,450.00View SEC Filing  
8/7/2014Gary PatouInsiderSell20,000$100.26$2,005,200.00View SEC Filing  
7/15/2014David M StackCEOSell15,000$86.75$1,301,250.00View SEC Filing  
7/14/2014Gary PatouInsiderSell29,700$86.96$2,582,712.00View SEC Filing  
7/10/2014Paul J HastingsDirectorSell2,500$84.41$211,025.00View SEC Filing  
6/6/2014Andreas WickiDirectorSell67,900$82.62$5,609,898.00View SEC Filing  
6/3/2014Andreas WickiDirectorSell68,000$80.69$5,486,920.00View SEC Filing  
5/27/2014Andreas WickiDirectorSell64,400$77.93$5,018,692.00View SEC Filing  
5/21/2014Andreas WickiDirectorSell3,600$77.80$280,080.00View SEC Filing  
5/12/2014Gary PatouInsiderSell30,000$74.39$2,231,700.00View SEC Filing  
5/9/2014David StackCEOSell25,000$73.94$1,848,500.00View SEC Filing  
5/9/2014Laura BregeDirectorSell10,000$73.85$738,500.00View SEC Filing  
5/8/2014Andreas WickiDirectorSell23,220$75.76$1,759,147.20View SEC Filing  
5/8/2014James ScibettaCFOSell15,000$75.05$1,125,750.00View SEC Filing  
5/7/2014Andreas WickiDirectorSell44,780$75.78$3,393,428.40View SEC Filing  
3/28/2014John Phd LongeneckerDirectorSell1,000$64.63$64,630.00View SEC Filing  
3/6/2014Andreas WickiDirectorSell24,887$80.16$1,994,941.92View SEC Filing  
12/30/2013David StackCEOSell15,000$55.84$837,600.00View SEC Filing  
12/30/2013James ScibettaCFOSell10,000$55.55$555,500.00View SEC Filing  
12/30/2013John Phd LongeneckerDirectorSell2,500$55.55$138,875.00View SEC Filing  
10/1/2013Gary PatouInsiderSell20,000$48.92$978,400.00View SEC Filing  
9/11/2013Andreas WickiDirectorSell17,783$37.25$662,416.75View SEC Filing  
8/14/2013Taunia MarkvickaVPSell14,700$37.00$543,900.00View SEC Filing  
7/22/2013Andreas WickiDirectorSell75,958$35.06$2,663,087.48View SEC Filing  
7/18/2013Andreas WickiDirectorSell25,560$33.45$854,982.00View SEC Filing  
7/16/2013Andreas WickiDirectorSell48,482$33.28$1,613,480.96View SEC Filing  
7/12/2013Taunia MarkvickaVPSell29,754$32.00$952,128.00View SEC Filing  
7/11/2013Andreas WickiDirectorSell80,000$31.48$2,518,400.00View SEC Filing  
7/5/2013Andreas WickiDirectorSell44,021$30.80$1,355,846.80View SEC Filing  
7/3/2013Andreas WickiDirectorSell114,448$30.21$3,457,474.08View SEC Filing  
7/2/2013Gary PatouInsiderSell40,000$29.44$1,177,600.00View SEC Filing  
6/28/2013David M StackCEOSell15,000$28.73$430,950.00View SEC Filing  
6/28/2013James S ScibettaCFOSell10,000$28.05$280,500.00View SEC Filing  
6/28/2013John P Phd LongeneckerDirectorSell2,000$28.09$56,180.00View SEC Filing  
6/24/2013Fred A MiddletonDirectorSell75,900$29.13$2,210,967.00View SEC Filing  
6/20/2013Fred A MiddletonDirectorSell144,100$29.32$4,225,012.00View SEC Filing  
6/19/2013Andreas WickiDirectorSell35,407$29.90$1,058,669.30View SEC Filing  
6/17/2013Andreas WickiDirectorSell50,145$29.86$1,497,329.70View SEC Filing  
6/13/2013John PrattInsiderSell21,032$30.00$630,960.00View SEC Filing  
6/13/2013Luke EvninDirectorSell22,746$30.07$683,972.22View SEC Filing  
6/12/2013Andreas WickiDirectorSell4,409$30.00$132,270.00View SEC Filing  
6/11/2013Andreas WickiDirectorSell11,500$30.00$345,000.00View SEC Filing  
6/11/2013John PrattInsiderSell18,343$30.00$550,290.00View SEC Filing  
6/5/2013Andreas WickiDirectorSell15,500$30.26$469,030.00View SEC Filing  
6/3/2013Andreas WickiDirectorSell1,900$30.00$57,000.00View SEC Filing  
5/31/2013Luke EvninDirectorSell54,517$30.00$1,635,510.00View SEC Filing  
5/29/2013Luke EvninDirectorSell215,528$30.86$6,651,194.08View SEC Filing  
5/22/2013Andreas WickiDirectorSell18,471$30.00$554,130.00View SEC Filing  
5/20/2013Andreas WickiDirectorSell14,374$30.00$431,220.00View SEC Filing  
3/25/2013Andreas WickiDirectorSell290,900$27.95$8,130,655.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateHeadline
News IconSell-side Taking Aim at Shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Aiken Advocate (NASDAQ:PCRX)
aikenadvocate.com - February 18 at 6:17 PM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Mean Price Target At ... - Transcript Daily (NASDAQ:PCRX)
transcriptdaily.com - February 18 at 6:17 PM
globenewswire.com logoPacira Pharmaceuticals, Inc. to Present at the 2017 RBC Capital Markets' Healthcare Conference - GlobeNewswire (press release) (NASDAQ:PCRX)
globenewswire.com - February 17 at 8:07 AM
News IconFollowing the Numbers for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Benton Bulletin (NASDAQ:PCRX)
bentonbulletin.com - February 16 at 11:46 PM
prnewswire.com logoHow These Healthcare Stocks are Faring? -- GlaxoSmithKline, Shire ... - PR Newswire (press release) (NASDAQ:PCRX)
www.prnewswire.com - February 16 at 11:46 PM
feeds.benzinga.com logoPacira Pharmaceuticals Announces Timing for 2016 Financial Results Webcast and Conference Call (NASDAQ:PCRX)
feeds.benzinga.com - February 16 at 8:14 AM
feeds.benzinga.com logoPacira Pharmaceuticals, Inc. to Present at the 2017 RBC Capital Markets' Healthcare Conference (NASDAQ:PCRX)
feeds.benzinga.com - February 15 at 11:12 AM
News IconEquity Rundown: Checking the Levels for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Midway Monitor (NASDAQ:PCRX)
midwaymonitor.com - February 14 at 11:10 PM
nasdaq.com logoImplied Volatility Surging for Pacira Pharmaceuticals (PCRX) Stock Options - Nasdaq (NASDAQ:PCRX)
www.nasdaq.com - February 14 at 11:10 PM
News IconEPS Target Of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)Set At $0.26 - Transcript Daily (NASDAQ:PCRX)
transcriptdaily.com - February 12 at 7:00 PM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Price Target Set At $51.8 - Transcript Daily (NASDAQ:PCRX)
transcriptdaily.com - February 11 at 1:10 AM
News IconTicker Scope: Tracking Shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Baldwin Journal (NASDAQ:PCRX)
baldwinjournal.com - February 11 at 1:10 AM
News IconMarket Update: Looking at the Levels for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Midway Monitor (NASDAQ:PCRX)
midwaymonitor.com - February 9 at 1:05 AM
News IconQuarterly EPS Of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Set ... - Stock Observer (NASDAQ:PCRX)
www.thestockobserver.com - February 4 at 5:59 AM
realistinvestor.com logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Mean Rating At $1.83 - RealistInvestor.com (NASDAQ:PCRX)
www.realistinvestor.com - January 31 at 12:52 AM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Daily Sentiment Score At 0.221 - Stock Observer (NASDAQ:PCRX)
www.thestockobserver.com - January 30 at 12:37 AM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Mean Price Target At $51.8 - Transcript Daily (NASDAQ:PCRX)
transcriptdaily.com - January 28 at 7:16 PM
realistinvestor.com logoEPS Projection Of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) At $0.26 - RealistInvestor.com (NASDAQ:PCRX)
www.realistinvestor.com - January 28 at 7:16 PM
News IconTrading Views: Checking the Numbers for Pacira Pharmaceuticals Inc. (PCRX) - Springdale Times (NASDAQ:PCRX)
springdaletimes.com - January 28 at 7:16 PM
News IconDeep Dive: Fund that almost tripled the S&P 500’s gain last year is now big on health-care stocks (NASDAQ:PCRX)
www.biggiesboxers.com - January 27 at 5:35 AM
us.rd.yahoo.com logo7:30 am Pacira Pharma announces an agreement with DePuy Synthes Sales to market and promote EXPAREL for orthopedic procedures in the US; co will host call at 8:30 AM ET to discuss (NASDAQ:PCRX)
us.rd.yahoo.com - January 25 at 11:33 PM
biz.yahoo.com logoPACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and (NASDAQ:PCRX)
us.rd.yahoo.com - January 25 at 11:33 PM
News IconMoving Averages in Focus on Shares of Pacira Pharmaceuticals Inc. (PCRX) - Springdale Times (NASDAQ:PCRX)
springdaletimes.com - January 25 at 5:59 AM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:PCRX)
www.thestockobserver.com - January 24 at 8:42 AM
realistinvestor.com logoMean Rating Of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) At $1.83 - RealistInvestor.com (NASDAQ:PCRX)
www.realistinvestor.com - January 24 at 8:42 AM
News IconWill The Needle Move For Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:PCRX)
wsbeacon.com - January 17 at 7:31 PM
News IconThe Technical Facts on Pacira Pharmaceuticals, Inc. (PCRX) - The USA Commerce (NASDAQ:PCRX)
theusacommerce.com - January 17 at 7:31 PM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Daily Sentiment Score At 0.31 - Stock Observer (NASDAQ:PCRX)
www.thestockobserver.com - January 16 at 9:56 AM
News IconPrice Target Of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) At $51.3 - Transcript Daily (NASDAQ:PCRX)
transcriptdaily.com - January 16 at 9:56 AM
News IconInvestor's Watch List: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX ... - The Newburgh Press (NASDAQ:PCRX)
newburghpress.com - January 14 at 5:43 AM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Quarterly EPS Set At $0.26 - Stock Observer (NASDAQ:PCRX)
www.thestockobserver.com - January 14 at 5:43 AM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Price Target Set At $51.3 - Transcript Daily (NASDAQ:PCRX)
transcriptdaily.com - January 13 at 12:48 AM
News IconPacira Pharmaceuticals, Inc. (PCRX) Rating Reiterated by Mizuho (NASDAQ:PCRX)
vouxmagazine.com - January 10 at 8:01 PM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Institutional Ownership stands at 0 (NASDAQ:PCRX)
myhealthbowl.com - January 10 at 8:01 PM
istreetwire.com logoStocks To Track: Pacira Pharmaceuticals, Inc. (PCRX), Texas Instruments Incorporated (TXN), Cypress Semiconductor ... - iStreetWire (NASDAQ:PCRX)
istreetwire.com - January 10 at 12:52 AM
News IconDaily Sentiment Score Of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) At 0.228 - Stock Observer (NASDAQ:PCRX)
www.thestockobserver.com - January 10 at 12:52 AM
rttnews.com logoPacira Pharmaceuticals Inc. (PCRX) Jumped On Preliminary Revenues (NASDAQ:PCRX)
www.rttnews.com - January 9 at 7:50 PM
biz.yahoo.com logoPACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:PCRX)
us.rd.yahoo.com - January 7 at 12:54 AM
publicnow.com logoPacira Pharmaceuticals Reports Preliminary 2016 Revenues of $276.4 Million (NASDAQ:PCRX)
us.rd.yahoo.com - January 7 at 12:54 AM
us.rd.yahoo.com logoPacira Pharmaceuticals shares rise after positive preliminary report (NASDAQ:PCRX)
us.rd.yahoo.com - January 7 at 12:54 AM
fool.com logoWhy Pacira Pharmaceuticals, Inc. Shares Shot 17% Higher Today (NASDAQ:PCRX)
www.fool.com - January 6 at 7:19 PM
seekingalpha.com logoPacira Pharmaceuticals reports preliminary 2016 revenues; shares up 4% premarket (NASDAQ:PCRX)
seekingalpha.com - January 6 at 9:40 AM
News IconBearish Target Of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) At $89 - Stock Observer (NASDAQ:PCRX)
www.thestockobserver.com - January 4 at 6:21 AM
News IconMarket Rating: Pacira Pharma (NASDAQ:PCRX) Gets Coverage From H.C. Wainwright with $43 PT (NASDAQ:PCRX)
www.whatsonthorold.com - January 3 at 10:20 AM
us.rd.yahoo.com logoCoverage initiated on Pacira Pharma by H.C. Wainwright (NASDAQ:PCRX)
us.rd.yahoo.com - January 3 at 10:20 AM
finance.yahoo.com logoPacira Pharmaceuticals, Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:PCRX)
finance.yahoo.com - January 3 at 10:20 AM
News IconDaily Sentiment Score Of Pacira Pharmaceuticals, Inc. (NASDAQ ... - Stock Observer (NASDAQ:PCRX)
www.thestockobserver.com - January 1 at 7:23 PM
News IconInvestor Wire: Keeping an Eye on Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Wall Street Beacon (NASDAQ:PCRX)
wsbeacon.com - December 31 at 1:17 AM
News IconInvestor Update: Looking at Shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Wall Street Beacon (NASDAQ:PCRX)
wsbeacon.com - December 26 at 6:30 PM
capitalcube.com logoPacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : December 26, 2016 (NASDAQ:PCRX)
www.capitalcube.com - December 26 at 9:42 AM

Social

What is Pacira Pharmaceuticals' stock symbol?

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

Where is Pacira Pharmaceuticals' stock going? Where will Pacira Pharmaceuticals' stock price be in 2017?

12 analysts have issued twelve-month price targets for Pacira Pharmaceuticals' stock. Their predictions range from $34.00 to $100.00. On average, they expect Pacira Pharmaceuticals' share price to reach $60.10 in the next twelve months.

When will Pacira Pharmaceuticals announce their earnings?

Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

Who owns Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (4.69%), State Street Corp (2.88%), Alyeska Investment Group L.P. (1.45%), Armistice Capital LLC (1.07%), Two Sigma Investments LP (0.64%) and Baillie Gifford & Co. (0.57%). Company insiders that own Pacira Pharmaceuticals stock include David M Stack, Gary W Pace, James B Jones, James S Scibetta, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings and Scott Braunstein.

Who sold Pacira Pharmaceuticals stock? Who is selling Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Highland Capital Management LP, State Street Corp, Frontier Capital Management Co. LLC and Guggenheim Capital LLC. Company insiders that have sold Pacira Pharmaceuticals stock in the last year include David M Stack, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker and Mark A Kronenfeld.

Who bought Pacira Pharmaceuticals stock? Who is buying Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Hodges Capital Management Inc., Armistice Capital LLC, Cortina Asset Management LLC, Alden Global Capital LLC, Two Sigma Investments LP, A.R.T. Advisors LLC and Bogle Investment Management L P DE. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include Gary W Pace, James B Jones, James S Scibetta, John P Phd Longenecker and Scott Braunstein.

How do I buy Pacira Pharmaceuticals stock?

Shares of Pacira Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Pacira Pharmaceuticals stock cost?

One share of Pacira Pharmaceuticals stock can currently be purchased for approximately $43.70.

Pacira Pharmaceuticals (NASDAQ:PCRX) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Earnings History Chart

Earnings by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Dividend History Chart

Dividend Payments by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Last Updated on 2/19/2017 by MarketBeat.com Staff